Applies to -- BIOP
BioPulse Insiders Lock-Up Nearly 80% of Shares Outstanding
BioPulse Insiders Lock-Up Nearly 80% of Shares Outstanding
SAN FRANCISCO, Nov 20, 2000 /PRNewswire via COMTEX/ -- BioPulse International
Inc., (OTC Bulletin Board: BIOP) today announced that six of the company's
largest shareholders have agreed to lock-up 6.6 million shares, representing
approximately 80% of the total number of fully diluted shares outstanding for a
period of one year.
John Liviakis, president and founder of Liviakis Financial Communications
commented, "Because of our long term commitment and strong belief in the future
of the company, insiders and our firm have agreed to the lock-up as a positive
gesture for shareholders and the financial community."
About BioPulse:
This fast growing, profitable, San Diego based Biotech company is enjoying high
success rates in treating cancer and other diseases. The company owns a
compelling portfolio of proprietary therapeutics and diagnostics, as well as
clinics that offer a comprehensive array of state-of-the-art procedures.
Various statements made within this press release may constitute
"forward-looking statements" for purposes of the Securities and Exchange
Commission's "safe harbor" provisions under the Private Securities Litigation
Reform Act of 1995 and Rule 3b-6 under the Securities Exchange Act of 1934. The
forward-looking statements contained herein involve risks and uncertainties that
could cause actual results to differ materially from those projected. The
Company undertakes no obligation to publicly release the result of any revision
to these forward-looking statements, which may be made to reflect the events or
circumstances after the date hereof or to reflect the occurrence of
unanticipated events. In addition to these risk factors, reference is made to
other risk factors and further information in the Company's public filings with
the Securities and Exchange Commission, including its reports on Form 10-SB/A
and 10Q-SB.
For more information, contact: John Liviakis, Liviakis Financial Communications
Inc., 415-389-4670; 415-389-4694 fax; mail to: moreinfo@lfcnet.com .
SOURCE BioPulse International Inc.
CONTACT: John Liviakis of Liviakis Financial Communications Inc.,
415-389-4670, or fax, 415-389-4694, or moreinfo@lfcnet.com, for BioPulse
International Inc.
URL: biopulse.com
prnewswire.com
(C) 2000 PR Newswire. All rights reserved.
-0-
KEYWORD: California
INDUSTRY KEYWORD: BIO
MTC
SUBJECT CODE: OTC
STOCK SYMBOLS: [(biop)]
Applies to -- BIOP
BioPulse President Presents 'Cancer Treatments on the Edge' at Whole Life Conference In Addition, the Company Moves Headquarters to San Diego Area
BioPulse President Presents 'Cancer Treatments on the Edge' at Whole
Life Conference
In Addition, the Company Moves Headquarters to San Diego Area
SAN YSIDRO, Calif., Nov 17, 2000 /PRNewswire via COMTEX/ -- BioPulse
International, Inc., (OTC Bulletin Board: BIOP) announces its President, Loran
Swensen, and Dr. Schramm will be presenting at the Whole Life Conference. The
convention starts today and will continue through November 19 in Los Angeles.
Mr. Swensen will be discussing BioPulse's revolutionary proprietary clinical
procedures in IHT (Insulin-Induced Hypoglycemic Therapy), their patent-pending
Dendritic Cell vaccine technology, and other state-of-the-art therapeutics and
diagnostics for cancer.
Clinics operated by BioPulse are currently conducting the worlds largest
clinical trials of Dendritic Cell Therapy.
In other news, BioPulse has relocated its headquarters recently to San Ysidro,
California (San Diego county).
About BioPulse:
This fast growing, profitable, San Diego based Biotech company is enjoying high
success rates in treating cancer and other diseases. The company owns a
compelling portfolio of proprietary therapeutics and diagnostics, as well as
clinics that offer a comprehensive array of state of the art procedures.
About Whole Life:
Whole Life has grown with the phenomenal success of the $60-billion-a-year
natural health, personal growth and spiritual development markets, while, at the
same time, responding to the needs of the community.
Whole Life's audience of affluent, well-educated, socially conscious consumers
who are interested in these areas is unparalleled. Beginning as Whole Life Expo
in San Francisco in 1982, Whole Life has expanded to 10 cities across the
nation. Since 1984, attendance has increased by 200 percent, regularly drawing
up to 20,000 attendees at each show; the number of exhibitors has also doubled.
Whole Life is committed to producing the most noteworthy and successful events
of its kind. As such, it attracts the nation's most outstanding contemporary
teachers and guides as its speakers. Best-selling authors such as Deepak Chopra,
Marianne Williamson, James Van Praagh, Wayne Dyer and James Redfield are Whole
Life regulars. Authors presenting workshops at this year's events have
collectively sold more than 100 million copies of their books.
Various statements made within this press release may constitute
"forward-looking statements" for purposes of the Securities and Exchange
Commission's "safe harbor" provisions under the Private Securities Litigation
Reform Act of 1995 and Rule 3b-6 under the Securities Exchange Act of 1934. The
forward-looking statements contained herein involve risks and uncertainties that
could cause actual results to differ materially from those projected. The
Company undertakes no obligation to publicly release the result of any revision
to these forward-looking statements, which may be made to reflect the events or
circumstances after the date hereof or to reflect the occurrence of
unanticipated events. In addition to these risk factors, reference is made to
other risk factors and further information in the Company's public filings with
the Securities and Exchange Commission, including its reports on Form 10-SB/A
and 10Q-SB.
SOURCE BioPulse International, Inc.
CONTACT: John Liviakis of Liviakis Financial Communications Inc.,
415-389-4670, or fax, 415-389-4694 or moreinfo@lfcnet.com
URL: biopulse.com
prnewswire.com
(C) 2000 PR Newswire. All rights reserved.
-0-
KEYWORD: California
INDUSTRY KEYWORD: BIO
MTC
SUBJECT CODE: TDS
Applies to -- BIOP
Leading Health Magazine Features Dendritic Cell Technology and BioPulse Dendritic Cell Market Forecasted at $15 Billion
Leading Health Magazine Features Dendritic Cell Technology and BioPulse
Dendritic Cell Market Forecasted at $15 Billion
SAN YSIDRO, Calif., Nov 16, 2000 /PRNewswire via COMTEX/ -- BioPulse
International, Inc. (OTC Bulletin Board: BIOP) today announced the upcoming
release of a cover article in Alternative Medicine Digest. The article entitled
"Tomorrow's Cancer Vaccine Today" will appear in the January 2001 issue and will
be available on the newsstands the first of December 2000
Magazine Excerpts:
"Dendritic cell therapy is being researched at the University of Heidelberg in
Germany, the Institute Curie in France and hospitals throughout Europe.
Practically every major medical center in the United States is involved in the
work: Memorial Sloan-Kettering, Cedars-Sinai, Dana Farber/Harvard Medical
School, M.D. Anderson and Johns Hopkins, to name just a few. They have been
conducting clinical trials with dendritic cell therapy for melanoma (skin
cancer) and prostate, breast, colon and other cancers with equally encouraging
outcomes.
"These institutions are associated with private-sector biotechnology companies
which are in a furious race to finish clinical trials, secure FDA approval and
bring patented vaccines to the market -- a Market estimated at $15 billion
annually. ... Aidan [BioPulse] has developed proprietary dendritic cell therapy
cancer protocols that are showing remarkable results. And the good news is this
biotechnology is available now."
About BioPulse:
This fast growing, profitable, San Diego-based Biotech company is enjoying high
success rates in treating cancer and other diseases. The company owns a
compelling portfolio of proprietary therapeutics and diagnostics, as well as
clinics which offer a comprehensive array of state of the art procedures.
Various statements made within this press release may constitute
"forward-looking statements" for purposes of the Securities and Exchange
Commission's "safe harbor" provisions under the Private Securities Litigation
Reform Act of 1995 and Rule 3b-6 under the Securities Exchange Act of 1934. The
forward-looking statements contained herein involve risks and uncertainties that
could cause actual results to differ materially from those projected. The
Company undertakes no obligation to publicly release the result of any revision
to these forward-looking statements, which may be made to reflect the events or
circumstances after the date hereof or to reflect the occurrence of
unanticipated events. In addition to these risk factors, reference is made to
other risk factors and further information in the Company's public filings with
the Securities and Exchange Commission, including its reports on Form 10-SB/A
and 10Q-SB.
SOURCE BioPulse International, Inc.
CONTACT: John Liviakis of Liviakis Financial Communications Inc.,
415-389-4670, or fax, 415-389-4694, or moreinfo@lfcnet.com
URL: biopulse.com
prnewswire.com
(C) 2000 PR Newswire. All rights reserved.
-0-
KEYWORD: California
INDUSTRY KEYWORD: BIO
HEA
SUBJECT CODE: OTC
STOCK SYMBOLS: [(biop)] |
